Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03422003 · ClinicalTrials.gov registry record · NA
Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast Carcinoma
A NA study of Breast Cancer, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- NA
- Development phase
- 400
- Enrollment target
- 15
- Study locations
NCT03422003 is a NA study of Breast Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 400 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (86% lower). The trial reports 15 study locations across 8 states.
The verdict
NCT03422003, a NA study of Breast Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 400 participants
- Enrollment target
- 15
- Study locations
Study Summary
This study is a randomized trial of hypofractionation (short-course) radiation therapy versus conventional radiation therapy in women who have undergone mastectomy and immediate breast reconstruction. The investigators will assess cosmetic and reconstruction outcomes, lymphedema, cancer status, side effects, and oncologic outcomes.
Conditions Studied
Interventions
- RADIATION Radiation Therapy
Study Locations (15)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana Farber Cancer Institute - Boston
- Massachusetts General Hospital/North Shore Center for Outpatient Care - Danvers
- Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) at Milford Regional Medical Center - Milford
- Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital - South Weymouth
California
- University of California, San Francisco - San Francisco
- Stanford University Medical Center - Stanford
Maine
- Eastern Maine Medical Center - Brewer
- Maine Medical Center - Scarborough
Colorado
- Vail Health - Edwards
Connecticut
- Yale Cancer Center - New Haven
District of Columbia
- Johns Hopkins Medicine - Washington D.C.
Rhode Island
- Lifespan/Rhode Island Hospital - Providence
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2018-04-01 |
| Est. Completion | 2030-04-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03422003
The ClinicalTrials.gov registry entry for NCT03422003 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (86% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Radiation Therapy is the first listed.
NCT03422003 reports 15 study locations spanning 8 distinct geographic areas - top geographies include Massachusetts, California, Maine.
Frequently Asked Questions
What is clinical trial NCT03422003 about?
NCT03422003 is a clinical study titled "Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast Carcinoma". This study is a randomized trial of hypofractionation (short-course) radiation therapy versus conventional radiation therapy in women who have undergone mastectomy and immediate breast reconstruction. The investigators will assess cosmetic and reconstruction outcomes, lymphedema, cancer status, side...
What is the current status of trial NCT03422003?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 400 participants. The study started on 2018-04-01. Estimated completion is 2030-04-01.
What conditions does trial NCT03422003 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT03422003?
The interventions under investigation include: Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT03422003?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03422003 being conducted?
This trial has 15 study locations across California, Colorado, Connecticut, District of Columbia, Maine. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.